1. Home
  2. ALAR vs APRE Comparison

ALAR vs APRE Comparison

Compare ALAR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$1.87

Market Cap

12.5M

Sector

Technology

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.67

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
APRE
Founded
2013
2006
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
11.5M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
ALAR
APRE
Price
$1.87
$0.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$14.00
$4.10
AVG Volume (30 Days)
146.7K
53.9K
Earning Date
05-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.51
N/A
Revenue Next Year
$33.43
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.62
$0.55
52 Week High
$18.00
$1.79

Technical Indicators

Market Signals
Indicator
ALAR
APRE
Relative Strength Index (RSI) 25.52 45.64
Support Level $1.62 $0.58
Resistance Level $7.54 $0.83
Average True Range (ATR) 0.13 0.05
MACD 0.24 0.01
Stochastic Oscillator 53.06 54.70

Price Performance

Historical Comparison
ALAR
APRE

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: